



Available online at

**ScienceDirect**  
[www.sciencedirect.com](http://www.sciencedirect.com)

Elsevier Masson France

**EM|consulte**  
[www.em-consulte.com/en](http://www.em-consulte.com/en)



## LETTERS TO THE EDITORS

### Response to the editorial “COVID-19 in patients with cardiovascular diseases”. Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of *Torsades de Pointes*

Réponse à l'éditorial, « Response to the editorial “COVID19 et maladies cardiovasculaires” »

**Keywords** Long QT syndrome; Chloroquine; Hydroxychloroquine; Azithromycin; *Torsade de Pointes*  
**Mots clés** Syndrome du QT long ; Chloroquine ; Hydroxychloroquine ; Azithromycine ; Torsade de Pointes

A recent editorial in this journal elegantly discussed the influence of cardiovascular diseases on COVID-19 [1]. Another issue is associated with the potential risk of cardiac arrhythmias with chloroquine or hydroxychloroquine (sometimes combined with azithromycin), which are being proposed to treat COVID-19. All three drugs individually can rarely provoke life-threatening polymorphic ventricular tachycardia, often in the setting of marked QT interval prolongation. However, the effects of their combination on this risk, particularly in critically ill patients, are unclear.

Chloroquine blocks  $I_{Kr}$  [2] –the main ionic current responsible for ventricular repolarisation–prolongs QT interval duration [3]; as a consequence, it can cause the malignant polymorphic ventricular tachycardia, *torsades de pointes*. The potential of hydroxychloroquine to prolong ventricular repolarisation is less well documented, but cases of QT prolongation and syncope have been reported during chronic treatment [4]. Azithromycin also mildly prolongs QT interval, possibly by different mechanisms [5], so its effect in combination with  $I_{Kr}$  blockers is unknown.

Patients with COVID-19 infection have multiple risk factors for this syndrome. Hypokalemia, in the 3.0–3.4 mmol/L range, is common. Fever amplifies drug-induced  $I_{Kr}$  blockade [6], and an increase in interleukin-6, as seen in COVID-19 infection [7], has been suggested as a mechanism of the QT prolongation associated with inflammation [8].

Until this risk is better evaluated in the context of the current pandemic, we urge physicians to monitor QT interval duration in patients with COVID-19 who are treated with

chloroquine or hydroxychloroquine alone or in combination with azithromycin. The following practical measures should be considered:

- record an electrocardiogram before treatment initiation if possible. If rate-corrected QT (QTc, by Bazett's formula, or preferably using the Fridericia formula) is > 500 ms (higher values may be considered if treatment is deemed life-saving in desperate cases), or if the patient is known to have had torsades de pointes or has the congenital long QT syndrome, do not start the drugs;
- avoid any other concomitant non-essential drugs known to prolong QT;
- supplement potassium to > 4 mmol/L;
- if QTc is long (> 480 ms) at baseline, obtain an electrocardiogram again 2–4 hours after the initial dose, and if possible, monitor heart rhythm. Consider stopping therapy if QTc > 520 ms is documented;
- continue to monitor the electrocardiogram as appropriate during treatment (e.g. every other day).

We believe that these simple actions will limit the occurrence of *torsade de pointes*. If it does occur, the patient can be treated with intravenous magnesium and/or isoproterenol and treatment with the offending drug(s) discontinued.

#### Sources of funding

None.

#### Disclosure of interest

The authors declare that they have no competing interest.

#### References

- [1] Hulot JS. COVID-19 in patients with cardiovascular diseases. Arch Cardiovasc Dis 2020, <http://dx.doi.org/10.1016/j.acvd.2020.03.009> [in press].
- [2] Borsini F, Crumb W, Pace S, et al. In vitro cardiovascular effects of dihydroartemisinin–piperaquine combination compared with other anti-malarials. Antimicrob Agents Chemother 2012;56:3261–70.
- [3] Vicente J, Zusterzeel R, Johannesen L, et al. Assessment of multi-ion channel block in a phase I randomised study design: results of the CiPA phase I ECG biomarker validation study. Clin Pharmacol Ther 2019;105:943–53.
- [4] Chen CY, Wang FL, Lin CC. Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. Clin Toxicol (Phila) 2006;44:173–5.
- [5] Yang Z, Prinsen JK, Bersell KR, et al. Azithromycin causes a novel proarrhythmic syndrome. Circ Arrhythm Electrophysiol 2017;10:e003560.

DOI of original article: <https://doi.org/10.1016/j.acvd.2020.03.009>.

Please cite this article in press as: Funck-Brentano C, et al. Response to the editorial “COVID-19 in patients with cardiovascular diseases”. Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of *Torsades de Pointes*. Arch Cardiovasc Dis (2020), <https://doi.org/10.1016/j.acvd.2020.04.001>

- [6] Kauthale RR, Dadarkar SS, Husain R, Karande VV, Gatne MM. Assessment of temperature-induced hERG channel blockade variation by drugs. *J Appl Toxicol* 2015;35:799–805.
- [7] Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020, [http://dx.doi.org/10.1016/S0140-6736\(20\)30566-3](http://dx.doi.org/10.1016/S0140-6736(20)30566-3) [in press].
- [8] Aromolaran AS, Srivastava U, Ali A, et al. Interleukin-6 inhibition of hERG underlies risk for acquired long QT in cardiac and systemic inflammation. *PLoS One* 2018;13:e0208321.

Christian Funck-Brentano<sup>a,\*</sup>, Joe-Elie Salem<sup>a</sup>, Lee S. Nguyen<sup>b</sup>, Milou-Daniel Drici<sup>c</sup>, Dan M. Roden<sup>d</sup>

<sup>a</sup> Pitié-Salpêtrière Hospital, AP–HP, Sorbonne Université, INSERM, CIC Paris-Est (CIC-1901), Department of Pharmacology, 75013 Paris, France

<sup>b</sup> Intensive Care Medicine department, Cochin University Hospital, AP–HP Centre, 75014 Paris, France

<sup>c</sup> Department of Pharmacology and Toxicology, Pharmacovigilance Centre, Hôpital de Cimiez, University of Nice Côte d'Azur Medical Centre, 06003, Nice, France

<sup>d</sup> Department of Medicine, Vanderbilt University Medical Centre, Nashville, TN, USA

\* Corresponding author at: Department of Pharmacology, Sorbonne Université, CIC Paris-Est, AP–HP, 47–83, boulevard de l'Hôpital, bât. de la Force, 75013 Paris, France.

E-mail address: [christian.funck-brentano@aphp.fr](mailto:christian.funck-brentano@aphp.fr) (C. Funck-Brentano)

Received 8 April 2020;  
accepted 9 April 2020

<https://doi.org/10.1016/j.acvd.2020.04.001>

1875-2136/© 2020 Elsevier Masson SAS. All rights reserved.